<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Noufou Ouédraogo</style></author><author><style face="normal" font="default" size="100%">W. Leila Marie Esther Belem-Kabré</style></author><author><style face="normal" font="default" size="100%">A.M. Emmanuel Thiombiano</style></author><author><style face="normal" font="default" size="100%">Tata Kadiatou Traoré</style></author><author><style face="normal" font="default" size="100%">Lazare Belemnaba</style></author><author><style face="normal" font="default" size="100%">Moussa Ouédraogo</style></author><author><style face="normal" font="default" size="100%">Innocent Pierre Guissou</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Anti-inflammatory Potential of Glycoside Flavonoids from Pterocarpus erinaceus Poir. (Fabaceae) Leaves</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Antioxidant</style></keyword><keyword><style  face="normal" font="default" size="100%">Compounds</style></keyword><keyword><style  face="normal" font="default" size="100%">Enzymes</style></keyword><keyword><style  face="normal" font="default" size="100%">Medicinal plant.</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style  face="normal" font="default" size="100%">August 2023</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">15</style></volume><pages><style face="normal" font="default" size="100%">593-598</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Background&lt;/strong&gt;: Chronic diseases have become one of the leading causes of death worldwide in recent years. Despite tremendous advances in the treatments of diseases, several concerns remain. Those with inflammatory components are alternatively treated or completed in Burkina Faso with medicinal plants. The present study was designed to identify and evaluate the anti-inflammatory potential of glycoside flavonoids from &lt;em&gt;Pterocarpus Erinaceus &lt;/em&gt;leaves. &lt;strong&gt;Methods: &lt;/strong&gt;The ﬂavonoids contained in &lt;em&gt;Pterocarpus Erinaceus&lt;/em&gt; aerial parts were extracted, identified, and characterized. Sequential soxhlet extraction was subjected to preliminary phytochemical screening, and characterization of isolated ﬂavonoid was done by U.V., I.R., 1H &amp;amp; 13C N.M.R. and MS. Subsequently, isolates were tested&lt;em&gt; in vitro&lt;/em&gt; for their antiinflammatory potential as well as their antioxidant capacities. &lt;strong&gt;Results: &lt;/strong&gt;Five compounds were determined as corresponding to 3’,4’,5,7-tetrahydroxy flavone (luteolin); quercetin-3-O- sophoroside; quercetin- 3-0-β-glucose (isoquercitrin); Kaempferol-3-O-sophoroside and 3,3’,4’,5,7-pentahydroxyflavone-3- rhamnoglucoside (rutin). Concentrations of quercetin-3-O- sophoroside and quercetin-3-0-β-glucose that inhibit 50% of pro-inflammatory enzymes’ activities were expressed in μg/mL. They were respectively 18.07 ± 0.78 and 32.27 ± 2.02 for xanthine oxidase, 1.12 ± 0.018 and 11.53 ± 0.52 for lipoxygenase, 26.91 ± 0.34 and 19.54 ± 0.25 for acetylcholinesterase. Prevention of the degradation of deoxyribose test gave respectively 19.32 ± 1.08 μg/mL and 26.21 ± 2.25 μg/mL for quercetin-3-O- sophoroside and quercetin-3-O- β-glucose while the anti-DPPH free radical potential was 3.41 ± 0.82 and 2.90 ± 0.18 μg/ mL. &lt;strong&gt;Conclusion: &lt;/strong&gt;These results may justify the traditional uses of P. erinaceus in treating diseases with an inflammatory component.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">4</style></issue><work-type><style face="normal" font="default" size="100%">Research Article</style></work-type><section><style face="normal" font="default" size="100%">593</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Noufou Ouédraogo&lt;sup&gt;1,3&lt;/sup&gt;, W. Leila Marie Esther Belem-Kabré&lt;sup&gt;1,2,&lt;/sup&gt;*, A.M. Emmanuel Thiombiano&lt;sup&gt;2&lt;/sup&gt;, Tata Kadiatou Traoré&lt;sup&gt;1,3&lt;/sup&gt;, Lazare Belemnaba&lt;sup&gt;1&lt;/sup&gt;, Moussa Ouédraogo&lt;sup&gt;3&lt;/sup&gt;, Innocent Pierre Guissou&lt;sup&gt;1&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Département Médecine et Pharmacopée Traditionnelles – Pharmacie (MEPHATRA-PH), Institut de Recherche en Sciences de la Santé (IRSS/CNRST), 03 BP 7047 Ouagadougou 03, BURKINA FASO.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Laboratoire de Biochimie et Chimie Appliquée (LABIOCA), Ecole Doctorale Sciences et Technologie, Université Joseph KI-ZERBO, 03 BP 7021 Ouagadougou 03, BURKINA FASO.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;3&lt;/sup&gt;Laboratoire de développement du médicament (LADME) / CEA-CFOREM, Ecole Doctorale Sciences de la Santé, Université Joseph KI-ZERBO 03 BP 7021 Ouagadougou 03, BURKINA FASO.&lt;/p&gt;
</style></auth-address></record></records></xml>